argenx announces launch of proposed initial public offering in the United States

argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that it intends to offer and sell, subject to the filing of a registration statement and market and other conditions, 3.6 million American Depositary Shares ("ADSs") representing 3.6 million ordinary shares in an initial public offering in the United States (the "Offering").

The final issuance price per ADS (in USD) sold in the Offering will be determined following the bookbuilding process. Each of the ADSs offered in the Offering represents the right to receive one ordinary share.

argenx's ordinary shares are currently listed on the regulated market of Euronext Brussels. argenx has made an application to have its ADSs listed on the NASDAQ Stock Market under the symbol "ARGX". Application will also be made to admit the ordinary shares, underlying the ADSs, issued pursuant to the Offering to trading on the regulated market of Euronext Brussels.

A registration statement relating to and describing the terms of the Offering has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. The ADSs may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

argenx intends to grant the underwriters of the Offering a 30-day option to purchase additional ordinary shares in the form of ADSs, provided that the number of such additional ADSs shall not exceed 15% of the ADSs sold in the Offering.

This press release is for information purposes only and does not constitute, and should not be construed as, an offer to sell or the solicitation of an offer to buy or subscribe to any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. Reference is also made to the restrictions set out in "Important information" below. This press release is not for publication or distribution, directly or indirectly, in or into any state or jurisdiction into which doing so would be unlawful or where a prior registration or approval is required for such purpose.

 

 

 

 

Note

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.  

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?